MDXHealth (MXDHF) Lifted to Hold at Zacks Investment Research
MDXHealth (OTCMKTS:MXDHF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “
MDXHealth (OTCMKTS:MXDHF) traded up $0.05 during trading hours on Wednesday, hitting $4.35. 2,000 shares of the stock were exchanged, compared to its average volume of 4,851. MDXHealth has a 12-month low of $3.80 and a 12-month high of $6.15.
WARNING: “MDXHealth (MXDHF) Lifted to Hold at Zacks Investment Research” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/mdxhealth-mxdhf-lifted-to-hold-at-zacks-investment-research/1806200.html.
MDxHealth SA, a molecular diagnostics company, develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients in Belgium and internationally. The companys tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MDXHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDXHealth and related companies with Analyst Ratings Network's FREE daily email newsletter.